Foster Dykema Cabot & Partners’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$27.8K Hold
124
﹤0.01% 215
2025
Q4
$29.9K Sell
124
-42
-25% -$10.7K ﹤0.01% 222
2025
Q3
$45.4K Hold
166
﹤0.01% 217
2025
Q2
$42.8K Hold
166
﹤0.01% 204
2025
Q1
$37.2K Hold
166
﹤0.01% 209
2024
Q4
$38K Sell
166
-134
-45% -$32.3K ﹤0.01% 220
2024
Q3
$73.2K Sell
300
-320
-52% -$71.5K 0.01% 188
2024
Q2
$119K Buy
+620
New +$126K 0.01% 135

Other funds holding RMD

Foster Dykema Cabot & Partners's RMD Position: Q1 2026 in Review

Foster Dykema Cabot & Partners held its ResMed (RMD) position steady in Q1 2026 at 124 shares worth $27.8K. The position accounts for ﹤0.01% of the portfolio, ranked #215.

Foster Dykema Cabot & Partners first reported a position in RMD in Q2 2024 and has held it in 8 quarters since. The position peaked at $119K in Q2 2024. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

  • Foster Dykema Cabot & Partners held 124 shares of ResMed worth $27.8K as of Q1 2026.
  • Foster Dykema Cabot & Partners left its ResMed share count unchanged in Q1 2026.
  • ResMed made up ﹤0.01% of Foster Dykema Cabot & Partners's portfolio in Q1 2026, its #215 holding.
  • Foster Dykema Cabot & Partners first reported a position in ResMed in Q2 2024 and has held it in 8 quarters since.
  • Foster Dykema Cabot & Partners's ResMed position peaked at $119K in Q2 2024.
  • 938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Foster Dykema Cabot & Partners's 13F filing for Q1 2026, filed 14 May 2026.